SARS-CoV-2 illness is associated with both pulmonary and extra pulmonary complications with hypoxemia being a marker of severity [1]. Evidence has shown an increase in venous thromboembolism (VTE) events both in intensive care unit (ICU) and non-ICU populations attributed to a multifactorial pathophysiological process [2,3]. Proximal disease related to true embolic event, distal disease representing thrombi related to the underlying inflammatory lung disease [4] and post-mortem data suggesting a possible role of small vessel micro thrombi contributes to the disease burden [5].
